These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32355826)

  • 1. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
    Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M
    Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
    Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
    Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
    [No Abstract]   [Full Text] [Related]  

  • 3. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
    Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
    Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept or ranibizumab for diabetic macular edema.
    Ali Ali MA; Hegazy HS; Abdelkhalek Elsayed MO; Tharwat E; Mansour MN; Hassanein M; Ezzeldin ER; GadElkareem AM; Abd Ellateef EM; Elsayed AA; Elabd IH; Abd Rbu MH; Amer RS; Gabbar AGAE; Mahmoud H; Abdelhameed HM; Abdelkader AME
    Med Hypothesis Discov Innov Ophthalmol; 2024; 13(1):16-26. PubMed ID: 38978826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
    Nawar AE; Wasfy T; Shafik HM
    BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.
    Spooner K; Hong T; Bahrami B; Chang A
    Acta Ophthalmol; 2019 Feb; 97(1):15-23. PubMed ID: 30251325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the efficacy of early switching from bevacizumab to aflibercept or ranibizumab in diabetic macular edema.
    Ataş M; Ozsaygılı C; Bayram N; Unal S
    Eur J Ophthalmol; 2022 Nov; ():11206721221137164. PubMed ID: 36330651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.
    Debourdeau E; Medard R; Chamard C; Nguyen V; Gabrielle PH; Creuzot-Garcher C; Allieu S; Gillies MC; Barthelmes D; Daien V;
    Ophthalmol Ther; 2023 Oct; 12(5):2657-2670. PubMed ID: 37505396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Initial Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema Is Significantly Correlated with Response to Third Consecutive Monthly Injection.
    Maeda S; Sugimoto M; Tenma Y; Tsukitome H; Kato K; Chujo S; Matsui Y; Matsubara H; Kondo M
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema.
    Klein KA; Cleary TS; Reichel E
    Int J Retina Vitreous; 2017; 3():16. PubMed ID: 28373914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review.
    Yuen YS; Tan GSW; Gan NY; Too IHK; Mothe RK; Basa P; Shaikh J
    Clin Ophthalmol; 2022; 16():3503-3526. PubMed ID: 36274678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.